2018
Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study
Visvanathan K, Shaw P, May BJ, Bahadirli-Talbot A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM. Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study. Cancer Prevention Research 2018, 11: canprevres.0009.2018. PMID: 30232083, PMCID: PMC6760670, DOI: 10.1158/1940-6207.capr-18-0009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCystadenocarcinoma, SerousDisease ProgressionFallopian Tube NeoplasmsFallopian TubesFemaleHumansMedical History TakingMiddle AgedOvarian NeoplasmsOvaryPrecancerous ConditionsPrevalencePrognosisProspective StudiesRetrospective StudiesSalpingo-oophorectomyConceptsSerous tubal intraepithelial lesionsHigh-grade serous ovarian carcinomaSerous tubal intraepithelial carcinomaP53 signatureRisk/protective factorsProtective factorsMultiple lesionsFallopian tubePrognosis of womenHigh-risk womenTubal intraepithelial carcinomaTubal intraepithelial lesionsSerous ovarian carcinomaPutative precursor lesionsYears of ageIntraepithelial lesionsIntraepithelial carcinomaMulticenter studyInvasive cancerOvarian carcinomaDisease progressionPrecursor lesionsEpidemiologic dataCombined prevalenceTubal lesions
2015
Shared genetics underlying epidemiological association between endometriosis and ovarian cancer
Lu Y, Cuellar-Partida G, Painter JN, Nyholt DR, Study A, Consortium T, Morris A, Fasching P, Hein A, Burghaus S, Beckmann M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty J, Rossing M, Wicklund K, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman M, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum I, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari L, Edwards R, Kelley J, Modugno F, Moysich K, Ness R, Cannioto R, Høgdall E, Jensen A, Giles G, Bruinsma F, Kjaer S, Hildebrandt M, Liang D, Lu K, Wu X, Bisogna M, Dao F, Levine D, Cramer D, Terry K, Tworoger S, Missmer S, Bjorge L, Salvesen H, Kopperud R, Bischof K, Aben K, Kiemeney L, Massuger L, Brooks-Wilson A, Olson S, McGuire V, Rothstein J, Sieh W, Whittemore A, Cook L, Le N, Gilks C, Gronwald J, Jakubowska A, Lubiński J, Gawełko J, Song H, Tyrer J, Wentzensen N, Brinton L, Trabert B, Lissowska J, Mclaughlin J, Narod S, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Gayther S, Gentry-Maharaj A, Menon U, Ramus S, Wu A, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham J, Fridley B, Winham S, Bandera E, Poole E, Morgan T, Risch H, Goode E, Schildkraut J, Webb P, Pearce C, Berchuck A, Pharoah P, Montgomery G, Zondervan K, Chenevix-Trench G, MacGregor S, Consortium T, Anderson C, Gordon S, Guo Q, Henders A, Lambert A, Lee S, Kraft P, Kennedy S, Macgregor S, Martin N, Missmer S, Montgomery G, Morris A, Nyholt D, Painter J, Roseman F, Treloar S, Visscher P, Wallace L, Zondervan K. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics 2015, 24: 5955-5964. PMID: 26231222, PMCID: PMC4581608, DOI: 10.1093/hmg/ddv306.Peer-Reviewed Original ResearchConceptsOvarian cancerEpidemiological associationGenetic correlationsSerous carcinomaFull genome coverageStrong genetic correlationLow-grade serous carcinomaHigh-grade serous carcinomaGenetic susceptibility lociClear cell carcinomaPolygenic architectureWeak genetic correlationsOvarian cancer datasetSusceptibility lociOvarian cancer susceptibilityPolygenic effectsCertain histotypesMucinous typeCell carcinomaEndometrioid carcinomaGenetic variantsFallopian tubeOvarian adenocarcinomaClear cellsEndometriosisOvarian cancer survival by tumor dominance, a surrogate for site of origin
Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J. Ovarian cancer survival by tumor dominance, a surrogate for site of origin. Cancer Causes & Control 2015, 26: 601-608. PMID: 25771796, PMCID: PMC4561551, DOI: 10.1007/s10552-015-0547-y.Peer-Reviewed Original ResearchConceptsDominant tumorHazard ratioFallopian tubeEstrogen hormone replacement therapyConclusionThese preliminary findingsHormone replacement therapyDistal fallopian tubeRisk of deathEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsProportional hazards modelSite of originTubal originWorse survivalReplacement therapyOvarian tumorsCancer survivalOvarian cancerPathology reportsOnly subtypeBRCA1/2 mutationsHazards modelObjectivesRecent studiesTumors